Glycolysis is observed virtually in cells of all types — eukaryotic and prokaryotic cells. In tumor cells, this pathway tends to be extremely upregulated (Warburg’s effect).
Many studies target the enzymes involved in the 10-step pathway to identify potential chemotherapeutic agents against various types of cancer. BioVision provides the most complete series of assays measuring various metabolite, cofactors and enzymes associated with the glycolytic pathway.
- Unique, specific assays
- Homogeneous, non-radioactive assays
- Validated: using mammalian cells, tissues, and biological fluids
- Economical: 100 assays; compatible with High Throughput Screening
- Convenient: quick protocols (1–2 hours); minimal sample preparation
Figure: Pyruvate Standard Curve: colorimetric (a), fluorometric (b). Quantitation of pyruvate in human saliva (c) and mouse liver lysate (d). Saliva sample was centrifuged at 10,000 x g for 10 min. at 4°C. Supernatant (10 µl) was spiked with known amounts of pyruvate Standard (6 nmol) and assayed according to kit protocol. Mouse liver homogenate was centrifuged and supernatant was collected. Supernatant was deproteinized using 10 kDa spin column (Cat. # 1997) and filtrate was diluted 5 fold. 10 ul of this diluted filtrate was spiked with known amount of pyruvate Standard (6 nmol) and assayed according to kit K609 protocol.
About BioVision Incorporated
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.
BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.